Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing a new class of antibiotics targeting difficult-to-treat bacterial infections caused by Gram-positive priority pathogens identified by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration. The company's innovative approach centers on inhibitors of the DNA polymerase IIIC enzyme, which is selective for Gram-positive bacteria. Its lead candidate, ibezapolstat, is an oral Gram-Positive Selective Spectrum antibiotic designed for Clostridioides difficile infections, demonstrating promising clinical results in Phase 2 trials with high cure rates and low recurrence. The research and development pipeline also includes early-stage candidates addressing infections from Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus, and Penicillin-Resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. holds key regulatory designations including FDA Qualified Infectious Disease Product and Fast Track status, as well as European Medicines Agency scientific advice and a positive pediatric investigation plan opinion. Founded in 2017 and headquartered in New York, New York, the company plays a vital role in combating antibiotic resistance through its specialized pol IIIC inhibitor platform.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. David P. Luci CPA, Esq., J.D.

Employees

4

Headquarters

Staten Island, NY, United States

Website

www.acurxpharma.com